Research location

West Monroe

Louisiana, United States

Published trials33

Site observations34

Linked trials published33

Page1 / 1

Research activity in West Monroe

Louisiana, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 33 trials and 34 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in West Monroe

33 linked trials · page 1 of 1

A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant HypercholesterolemiaNCT07610278 · 2026-05-29 · 1 site observation

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2NCT07288398 · 2026-03-03 · 1 site observation

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation

Collaborative Multi-level Obesity Intervention Engaging Communities TrialNCT06835686 · 2025-03-14 · 1 site observation

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 1 site observation

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor AntagonistsNCT06033950 · 2024-08-20 · 1 site observation

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)NCT06024746 · 2024-07-09 · 1 site observation

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsNCT06008197 · 2024-01-17 · 1 site observation

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASHNCT06410924 · 2024-06-13 · 1 site observation

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection FractionNCT06017609 · 2023-12-20 · 1 site observation

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic RetinopathyNCT05393284 · 2022-08-16 · 1 site observation

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood PressureNCT04714320 · 2021-04-28 · 1 site observation

Fenofibrate for Prevention of DR WorseningNCT04661358 · 2021-03-05 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)NCT04469595 · 2020-08-31 · 1 site observation

ACTIVE_NOT_RECRUITING

Before-after Comparison of Pharmacist Drug Therapy Management in Pediatric HypertensionNCT04098978 · 2020-01-14 · 1 site observation

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)NCT03888066 · 2019-04-24 · 1 site observation

Benefits of µCor in Ambulatory Decompensated Heart FailureNCT03476187 · 2018-08-17 · 1 site observation

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.NCT03448406 · 2018-03-20 · 1 site observation

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure SymptomsNCT03448419 · 2018-03-20 · 1 site observation

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02NCT03426345 · 2018-02-16 · 1 site observation

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04NCT03383146 · 2018-02-01 · 1 site observation

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03NCT03420781 · 2018-01-24 · 1 site observation

PROMINENT-Eye Ancillary Study (Protocol AD)NCT03345901 · 2018-01-15 · 2 site observations

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · 2017-01-06 · 1 site observation

Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.NCT02887183 · 2016-10-25 · 1 site observation

Anti-VEGF Treatment for Prevention of PDR/DMENCT02634333 · 2016-01-01 · 1 site observation

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic GastroparesisNCT02357420 · 2015-01-29 · 1 site observation

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and HypertensionNCT01031680 · 2010-02-01 · 1 site observation

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy AloneNCT00295633 · 2006-03-01 · 1 site observation

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)NCT00297115 · 2006-03-01 · 1 site observation

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin AloneNCT00121667 · 2005-08-01 · 1 site observation

Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseNCT00121641 · 2005-07-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.